Stratosvir Limited

Stratosvir Limited specializes in the development of innovative viral immunotherapy solutions designed to transform cancer treatment by targeting solid tumors and enhancing immune response. Stratosvir Ltd. , founded in 2020 in the UK, focuses on viral immunotherapy for cancer treatment. The company has executed a single deal as of April 17, 2024.

The founder has a history of leading ventures in the biotech industry, although specific details about other companies were not provided. Stratosvir develops viral immunotherapy solutions aimed at treating cancer by utilizing engineered viruses that selectively target and destroy malignant cells while enhancing immune response. The company primarily focuses on solid tumors and is targeting the oncology market in regions such as Europe, specifically the UK and Germany, where they have secured collaborative R&D grants from cancer organizations. Their products are designed for healthcare providers and oncology specialists, aiming to offer effective and non-toxic treatment alternatives.

Stratosvir's revenue model is based on partnerships and investments from health and cancer organizations, structured as collaborative agreements that support their research and development initiatives. The company collaborates with institutions wishing to integrate innovative oncological solutions into their treatment protocols. Although specific pricing plans for their products are not publicly disclosed, their offerings are likely integrated into clinical trial frameworks. In April 2024, Stratosvir Ltd.

raised an undisclosed amount of venture funding from new investor o2h Ventures. This funding will be utilized to further develop their Viral Immunotherapy for Late-Stage Cancer. The company is focusing on expanding its product offerings and plans to target new geographic markets, although specific regions and timelines for expansion were not detailed.